Streetbeat News

Products Services

ABBV

LULU

SYY

TJX

On CNBC's 'Halftime Report Final Trades,' analysts recommended TJX Companies, AbbVie, Sysco, and Lululemon. TJX reported strong Q1 FY25 results, AbbVie received positive CHMP opinion for SKYRIZI®, Sysco missed Q3 FY24 sales estimates, and Lululemon announced an updated operational structure.

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 12:30 pm

BCTX

BriaCell presented promising clinical efficacy data for its Bria-IMT therapy in a Phase 2 study for advanced metastatic breast cancer at ASCO 2024. The therapy showed doubled Progression-Free-Survival (PFS) and Clinical Benefit Rate compared to historical results, and was well-tolerated with no related discontinuations.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:29 pm

AAPL

LOW

Lowe's has launched an Apple Vision Pro-powered in-store experience, starting with a pilot in three test markets this month. Customers can use Lowe's Style Studio and spatial computing to visualize and design their dream kitchens.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:28 pm

REPL

Replimune Group, Inc. (NASDAQ: REPL) presented promising clinical data from its RP1 and RP2 programs at the 2024 ASCO Annual Meeting. The 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma showed an overall response rate of 32.7%. Additionally, RP2 as monotherapy and in combination with nivolumab in uveal melanoma demonstrated an overall response rate of nearly 30%.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:26 pm

NKGN

NKGen Biotech will present updated Phase 1 data of its SNK02 allogeneic NK cell therapy in solid tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:26 pm

BRK

JPM

MSFT

NVDA

Nvidia Corp (NASDAQ:NVDA) experienced a significant market cap increase of $350 billion due to a gamma squeeze, driven by a surge in call options. The company's market cap reached $2.69 trillion, surpassing JPMorgan Chase & Co (NYSE:JPM) and Berkshire Hathaway Inc (NYSE:BRK). Nvidia's Q1 earnings report and its role in generative AI were key catalysts. The event highlights both opportunities and risks for investors.

Portfolio Pulse from Surbhi Jain

June 03, 2024 | 12:26 pm

BDRX

Biodexa Pharmaceuticals reported positive Phase 2 data results for its drug eRapa, showing a 24% reduction in total polyp burden and an 83% non-progression rate, indicating high efficacy in preventing polyp growth.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:23 pm

MTEK

Maris-Tech has received a $225,000 order from Aero Sol for an advanced video payload solution for drones, based on its Uranus technology.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:23 pm

SCPX

Scorpius Holdings, Inc. (NYSE American: SCPX) has announced a strategic partnership with Beyond Imagination, Inc. to utilize autonomous AI-powered humanoid robots in American biomanufacturing. This collaboration aims to improve biomanufacturing reliability, scalability, and efficiency, and enhance US preparedness for pandemics and other crises.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:22 pm

ME

23andMe Holding Co. (NASDAQ:ME) presented positive preliminary Phase 2 safety and efficacy data for its anti-CD200R1 antibody, 23ME-00610, at the 2024 ASCO Annual Meeting. The data showed clinical benefits, including a confirmed partial response, and acceptable safety and tolerability.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:22 pm